Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 3Recruiting 3Unknown 2Completed 2Suspended 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1

Conditions

Lymphoma 1600Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Leukemia, Lymphocytic, Chronic, B-Cell 1090Lymphoma, Follicular 979Lymphoma, Large B-Cell, Diffuse 853Leukemia 790Hodgkin Disease 777Lymphoma, Mantle-Cell 675Leukemia, Myeloid, Acute 540Burkitt Lymphoma 507Lymphoma, B-Cell, Marginal Zone 490Multiple Myeloma 483Myelodysplastic Syndromes 371Lymphoma, Large-Cell, Immunoblastic 366Recurrence 363Lymphoma, T-Cell, Cutaneous 313Neoplasms 309Waldenstrom Macroglobulinemia 307Lymphoma, Large-Cell, Anaplastic 254Mycosis Fungoides 252Lymphoma, B-Cell 231Sezary Syndrome 229Blast Crisis 210Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 208Myeloproliferative Disorders 205Leukemia, Myelogenous, Chronic, BCR-ABL Positive 189Neoplasms, Plasma Cell 188Leukemia, Myeloid, Accelerated Phase 186Leukemia, Myeloid, Chronic-Phase 179

Interventions

tocilizumab 1siltuximab 1Zidovudine 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Castleman Disease × Lymphoid × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡